217 related articles for article (PubMed ID: 24367658)
1. Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
Ross RL; Burns JE; Taylor CF; Mellor P; Anderson DH; Knowles MA
PLoS One; 2013; 8(12):e84411. PubMed ID: 24367658
[TBL] [Abstract][Full Text] [Related]
2. PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer.
Urick ME; Rudd ML; Godwin AK; Sgroi D; Merino M; Bell DW
Cancer Res; 2011 Jun; 71(12):4061-7. PubMed ID: 21478295
[TBL] [Abstract][Full Text] [Related]
3. The p85alpha subunit of phosphatidylinositol 3'-kinase binds to and stimulates the GTPase activity of Rab proteins.
Chamberlain MD; Berry TR; Pastor MC; Anderson DH
J Biol Chem; 2004 Nov; 279(47):48607-14. PubMed ID: 15377662
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived mutations within the N-terminal domains of p85α impact PTEN or Rab5 binding and regulation.
Mellor P; Marshall JDS; Ruan X; Whitecross DE; Ross RL; Knowles MA; Moore SA; Anderson DH
Sci Rep; 2018 May; 8(1):7108. PubMed ID: 29740032
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.
Echeverria I; Liu Y; Gabelli SB; Amzel LM
FEBS J; 2015 Sep; 282(18):3528-42. PubMed ID: 26122737
[TBL] [Abstract][Full Text] [Related]
6. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.
Cheung LW; Hennessy BT; Li J; Yu S; Myers AP; Djordjevic B; Lu Y; Stemke-Hale K; Dyer MD; Zhang F; Ju Z; Cantley LC; Scherer SE; Liang H; Lu KH; Broaddus RR; Mills GB
Cancer Discov; 2011 Jul; 1(2):170-85. PubMed ID: 21984976
[TBL] [Abstract][Full Text] [Related]
7. PI3K/AKT pathway activation in bladder carcinogenesis.
Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
[TBL] [Abstract][Full Text] [Related]
8. PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.
Thorpe LM; Spangle JM; Ohlson CE; Cheng H; Roberts TM; Cantley LC; Zhao JJ
Proc Natl Acad Sci U S A; 2017 Jul; 114(27):7095-7100. PubMed ID: 28630349
[TBL] [Abstract][Full Text] [Related]
9. Regulation of the PI3K pathway through a p85α monomer-homodimer equilibrium.
Cheung LW; Walkiewicz KW; Besong TM; Guo H; Hawke DH; Arold ST; Mills GB
Elife; 2015 Jul; 4():e06866. PubMed ID: 26222500
[TBL] [Abstract][Full Text] [Related]
10. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.
Sun M; Hillmann P; Hofmann BT; Hart JR; Vogt PK
Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15547-52. PubMed ID: 20713702
[TBL] [Abstract][Full Text] [Related]
11. A p85 isoform switch enhances PI3K activation on endosomes by a MAP4- and PI3P-dependent mechanism.
Thapa N; Chen M; Cryns VL; Anderson R
Cell Rep; 2024 May; 43(5):114119. PubMed ID: 38630589
[TBL] [Abstract][Full Text] [Related]
12. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.
Hon WC; Berndt A; Williams RL
Oncogene; 2012 Aug; 31(32):3655-66. PubMed ID: 22120714
[TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
Dornan GL; Burke JE
Front Immunol; 2018; 9():575. PubMed ID: 29616047
[TBL] [Abstract][Full Text] [Related]
14. Impact of p85α Alterations in Cancer.
Marshall JDS; Whitecross DE; Mellor P; Anderson DH
Biomolecules; 2019 Jan; 9(1):. PubMed ID: 30650664
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice.
Foth M; Ahmad I; van Rhijn BW; van der Kwast T; Bergman AM; King L; Ridgway R; Leung HY; Fraser S; Sansom OJ; Iwata T
J Pathol; 2014 Jun; 233(2):148-58. PubMed ID: 24519156
[TBL] [Abstract][Full Text] [Related]
16. Cancer-associated mutations in the p85α N-terminal SH2 domain activate a spectrum of receptor tyrosine kinases.
Li X; Lau AYT; Ng ASN; Aldehaiman A; Zhou Y; Ng PKS; Arold ST; Cheung LWT
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34507989
[TBL] [Abstract][Full Text] [Related]
17. Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions.
Hao Y; Wang C; Cao B; Hirsch BM; Song J; Markowitz SD; Ewing RM; Sedwick D; Liu L; Zheng W; Wang Z
Cancer Cell; 2013 May; 23(5):583-93. PubMed ID: 23643389
[TBL] [Abstract][Full Text] [Related]
18. Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
Dornan GL; Stariha JTB; Rathinaswamy MK; Powell CJ; Boulanger MJ; Burke JE
Structure; 2020 Feb; 28(2):145-156.e5. PubMed ID: 31831213
[TBL] [Abstract][Full Text] [Related]
19. Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85α regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain.
Hofmann BT; Jücker M
Cell Signal; 2012 Oct; 24(10):1950-4. PubMed ID: 22735814
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs.
Ross RL; Askham JM; Knowles MA
Oncogene; 2013 Feb; 32(6):768-76. PubMed ID: 22430209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]